Ace Therapeutics Launches Gene Therapy Development Services to Unleash Glaucoma Drug Research
Nyenta.com/10297074

Trending...
NEW YORK - Nyenta -- Ace Therapeutics, a contract research organization (CRO) based in the United States, is excited to announce the launch of its groundbreaking glaucoma gene therapy development services (https://www.acetherapeutics.com/glaucoma/gene-t...). This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease.

Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high intraocular pressure. Gene therapy for glaucoma is a promising field of research focused on developing treatments to address the underlying causes of the disease, potentially offering more effective and long-lasting solutions than current options. For example, utilizing CRISPR/Cas9 and other genome-editing tools, scientists are exploring ways to correct mutations that lead to glaucoma. This method could provide a more permanent solution by addressing the root genetic causes of the disease. As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials.

More on Nyenta.com
As an innovative ophthalmic disease research company with a wide range of services in basic research, drug development, and preclinical studies, Ace Therapeutics has expanded its portfolio to include gene therapy solutions designed specifically to accelerate glaucoma drug discovery and development. "Our mission at Ace Therapeutics has always been to push the boundaries of science to deliver life-changing therapies," said the business development manager of Ace Therapeutics. "With the launch of our gene therapy development services, we are forging new pathways in glaucoma research, harnessing cutting-edge technologies to unlock potential cures that were once thought beyond reach."

Ace Therapeutics' gene therapy development services for glaucoma offer comprehensive solutions that include stem cell-based gene therapy development, siRNA development, gene delivery system engineering, and preclinical testing. Based on years of CRO experience, Ace Therapeutics' integrated development pipeline ensures a seamless end-to-end process, from initial discovery through to preclinical validation, designed to streamline the development timeline and enhance success rates.

More on Nyenta.com
Ace Therapeutics is a pioneer in ophthalmic diseases, dedicated to providing supportive research services to advance scientific study and improve research outcomes. With the commitment to bridge the gap between scientific discoveries and clinical applications, Ace Therapeutics has established strategic partnerships with academic institutions and biotech firms to foster collaboration and innovation.

About Ace Therapeutics

Ace Therapeutics Glaucoma (https://www.acetherapeutics.com/glaucoma/) is an innovative eye disease research company that offers a wide range of services in basic research, drug development, and preclinical studies, delivering high-quality and customized solutions to worldwide clients. Based on integrated drug development platform and comprehensive disease models, Ace Therapeutics empowers researchers and pharmaceuticals the necessary expertise and tools to accelerate ophthalmic disease research outcomes.

Contact
Ace Therapeutics
***@acetherapeutics.com


Source: Ace Therapeutics
Show All News | Report Violation

0 Comments

Latest on Nyenta.com